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Abstract 
Background: Indole pyruvic acid (IPA) is a versatile platform intermediate and building block for a number of high-
value products in the pharmaceutical and food industries. It also has a wide range of applications, such as drugs for 
the nervous system, cosmetics, and luminophores. Chemical synthesis of IPA is a complicated and costly process. 
Moreover, through the biosynthesis route employing l-amino acid oxidase, the byproduct hydrogen peroxide leads 
the degradation of IPA. TdiD, identified as a specific tryptophan aminotransferase, could be an alternative solution for 
efficient IPA biosynthesis.
Results: Escherichia coli strain W3110, which demonstrates basic production when supplied with tryptophan, was 
engineered for IPA biosynthesis. Several strategies were implemented to improve IPA production. First, through incor-
porating the codon-optimized tdiD into W3110, IPA levels increased from 41.54 ± 1.26 to 52.54 ± 2.08 mg/L. Second, 
after verifying the benefit of an increased phenylpyruvate pool, a YL03 strain was constructed based on a previously 
reported mutant strain of W3110 with a plasmid carrying aroFfbr and pheAfbr to further improve IPA production. The 
recombinant YL03 strain accumulated IPA at 158.85 ± 5.36 mg/L, which was 3.82-fold higher than that of the wild-
type W3110 strain. Third, optimization of tdiDco expression was carried out by replacing the Trc promoter with a series 
of constitutively active promoters along with increasing the plasmid copy numbers. The highest IPA production was 
observed in YL08, which achieved 236.42 ± 17.66 mg/L and represented a greater than 5-fold increase as compared 
to W3110. Finally, the effects of deletion and overexpression of tnaA on IPA biosynthesis were evaluated. The removal 
of tnaA led to slightly reduced IPA levels, whereas the overexpression of tnaA resulted in a considerable decline in 
production.
Conclusions: This study illustrates the feasibility of IPA biosynthesis in E. coli through tdiD. An efficient IPA producing 
strain, YL08, was developed, which provides a new possibility for biosynthesis of IPA. Although the final production 
was limited, this study demonstrates a convenient method of IPA synthesis.
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Background
Indole pyruvic acid (IPA) is well known as the first step 
product in the IPA-pathway of the plant hormone indole-
3-acetic acid (IAA) biosynthesis [1]. IPA is also used 
as the precursor of the sweetener monatin [2] (Fig.  1). 
Chromopyrrolic acid can be produced from IPA directly, 
thereby generating indolocarbazole compounds with 
antitumor activities, such as staurosporine [3] (Fig.  1) 
and rebeccamycin [4]. Furthermore, IPA constitutes the 
fundamental building block of bis-indolylquinones, such 
as terrequinone A [5] (Fig. 1), semicochliodinol, and hin-
nuliquinone [6]. In recent decades, owing to their antiret-
roviral, anti-diabetes and cytotoxic bioactivities, these 
compounds have garnered significant attention [6].
Moreover, IPA itself is of high pharmaceutical impor-
tance. IPA has analgesic and sedative properties, par-
ticularly, its analgesic action does not induce drug 
resistance [7]. For anxious people, IPA is a safe drug with-
out withdrawal effects, and can help people release stress 
as well as generate feelings of relaxation and happiness 
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[8]. Besides, IPA counteracts endocrine improvement 
during stressful situations [9]. After administration, ser-
otonin and melatonin are the most prominent products 
of IPA, which have positive effects on insomnia [10]. As 
a neuronal protecting agent [11], IPA maintains its anti-
oxidant function to inhibit radical damage, and thus 
protects the brain from pathological impairment dur-
ing aging [12]. In addition, IPA is patented as a cosmetic 
agent for sun protection and anti-aging [13]. And it could 
be a potential source of luminophores due to the charac-
teristics of its chemiluminescence spectrum [14].
The chemical methods for IPA synthesis use either 
indole or tryptophan (Trp) as the initial raw material, 
but the procedures are complicated and costly [15, 16]. 
Biosynthesis, on the other hand, has a lot of advantages. 
Employing an l-amino acid oxidase or aminotransferase, 
Escherichia coli was able to successfully produce IPA 
from L-Trp [17, 18]. For the l-amino acid oxidase cata-
lytic reaction, the synthesis of IPA is accompanied by the 
generation of hydrogen peroxide in equivalent mole ratio 
to IPA. Hydrogen peroxide can induce IPA degradation. 
Therefore, catalase activity either from the inducible and 
endogenous E. coli catalase [19] or exogenous catalase 
expression is required, in order to ensure IPA protection 
from the degradation mediated by hydrogen peroxide. 
Nevertheless, the remaining hydrogen peroxide can lead 
to oxidative stress [20, 21] as well as the undesired oxi-
dation of further product. Therefore, elaborate regulation 
of catalase expression is necessary. However, through 
amino acid aminotransferase (AAT), the other product 
in addition to IPA would be an amino acid correspond-
ing to the amino acceptor. Unlike the IPA biosynthesis 
process catalyzed by amino acid oxidase, no further steps 
were needed to remove the toxic byproduct and modu-
late redox balance when an AAT is utilized. Moreover, 
the accumulation of an amino acid as the other product, 
which is of great commercial value [22], provides an extra 
economic benefit. Therefore, in order to develop a uni-
versally applicable platform to improve IPA production 
and facilitate the biosynthesis of the follow-up sophis-
ticated compound, utilization of an AAT is the optimal 
approach.
There are several AATs in E. coli. Similar to aspar-
tate aminotransferase (AspC) and aromatic amino acid 






































Fig. 1 IPA synthesis reaction catalyzed by TdiD and IPA applications
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aminotransferase (TyrB), almost all of these enzymes 
are multispecific [23], and responsible for the synthesis 
of corresponding amino acids. In order to construct an 
IPA biosynthetic pathway with concise route, which can 
be accurately controlled without concerns for substrate 
preference, the utilization of an AAT with substrate 
specificity for Trp is desirable. Recently, with the elucida-
tion of the terrequinone A biosynthesis pathway [5], tdiD 
derived from Aspergillus nidulans was characterized as 
an l-tryptophan:phenylpyruvate aminotransferase [6] 
(Fig. 1). This finding encourages the exploration of a new 
approach for IPA biosynthesis with TdiD in which only 
one catalysis step is needed to produce IPA from Trp. 
In this study, we demonstrate the construction of a new 
pathway for IPA production. The IPA producing path-
way was established through recombinant expression of 
codon-optimized tdiD (tdiDco). IPA production was sub-
sequently improved by increasing the substrate availabil-
ity, blocking the branch pathway, and optimizing tdiDco 
expression. The influence of tnaA was also investigated in 
detail. Finally, an effective IPA production strain that can 
be engineered for further bioactive compound synthesis 
was developed. The procedure reported here represents 
a new vision into IPA biosynthesis and provides valuable 
perspective for this biological route.
Results and discussion
The incorporation of tdiD into E. coli W3110
TdiD catalyzes the transamination of L-Trp to form IPA. 
The two substrates, L-Trp and phenylpyruvate (PPA), are 
downstream metabolites of the shikimate pathway in E. 
coli. In addition to IPA, the other product is phenylala-
nine (Phe) which has extensive applications, functioning 
as a nutraceutical as well as the precursor for the gen-
eration of food additives and pharmaceutically active 
compounds [22]. Here, we managed to improve the 
production of IPA using the transaminase TdiD supple-
mented with 2 g/L Trp.
tdiDco under the control of the Trc promoter was 
inserted into the medium-copy-number pET24b and 
named pTRCD (Table  1). Thus, E. coli strain WTRCD 
(Table 1) transformed pTRCD exhibited moderate TdiD 
expression. There was no distinct difference between 
W3110 and WTRCD in cell growth (Fig. 2a), indicating 
no detrimental effects caused by the existence of pTRCD. 
The WTRCD strain displayed enhanced IPA levels com-
pared to the W3110 strain. Generally, the IPA produc-
tion of W3110 and WTRCD increased continuously 
within 0–25 h, and maxed after 25 h of cultivation (the 
0  h of cultivation started at the point of IPTG induc-
tion). At 25 h, the WTRCD strain produced a final titer 
of 52.54 ± 2.08 mg/L IPA, which is 26.48% more than the 
IPA produced in the W3110 strain (41.54 ± 1.26 mg/L) 
(Fig. 2b). After 25 h, IPA levels started to decrease in both 
strains, which can be ascribed to the decomposition [26]. 
However, the IPA production of W3110 strain declined 
sharply while the IPA production in WTRCD strain 
decreased gradually (Fig. 2b). W3110 demonstrates basic 
IPA production due to the inherent multispecific AATs, 
which could convert Trp into IPA when supplied with 
Trp. AspC and TyrB, which have been used for IPA syn-
thesis as an intermediate step in previous reports [1, 18], 
were considered as the main enzymes for the IPA basic 
production in W3110 strain. And this assumption has 
been verified by the negligible IPA production in the aspC 
and tyrB mutants strain which is indicated in the follow-
ing section (Fig. 4b). AspC is in favor of the reverse reac-
tion converting IPA to Trp [27, 28]. On the other hand, 
though TyrB catalyzes the reaction with a much lower 
Km than AspC [29], its expression is severely repressed 
by the products [30, 31]. Therefore, after 25 h cultivation, 
IPA biosynthesis in W3110 were repressed while the con-
sumption and degradation of IPA continued, resulting in 
the dramatically reduced IPA concentration.
PPA feeding experiment
Equal molar amounts of Trp and PPA are needed for IPA 
biosynthesis through TdiD. The availability of both sub-
strates is crucial for achieving the maximum production 
of IPA. Although an endogenous metabolite, native PPA 
might exist at a trace quantity. Thus, the insufficiency 
of PPA could be a bottleneck of the IPA biosynthesis in 
WTRCD strain. In order to investigate this possibility, 
sodium PPA (1.86 g/L, 10 mM) was added together with 
0.5 mM IPTG at the same time to the medium contain-
ing Trp (2 g/L, 10 mM). The growth rate, substrate, and 
products concentrations were constantly monitored. As 
shown in Fig.  2, after PPA addition, cell growth of the 
WTRCD strain was hindered at the initial stage, although 
the final cell density was similar to that of the control. IPA 
production increased quickly from 0 to 5 h and reached 
23.52  ±  3.71  mg/L at 5  h, which was approximately 3 
times higher than that in the WTRCD strain without 
PPA supplementation. During the 5–20  h incubation 
time, IPA production of the WTRCD strain with PPA 
was enhanced 2- to 3-fold compared to the strain with-
out PPA. However, the advantage in production disap-
peared after 20 h and the final IPA amount produced by 
WTRCD with PPA was only slightly higher than that of 
the strain without PPA (Fig. 2b). This decline might due 
to the rapid reduction in PPA levels over time. The rela-
tive concentration of PPA dropped from 100 to 25.27% 
in 10  h, remained 3.22% at 15  h, and was undetectable 
after 20  h (Fig.  2c). The maximum amount of Phe was 
observed at 20 h with a concentration of 0.86 ± 0.06 g/L 
(5.21 mM). This suggested that only 52.10% of PPA had 
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been subjected to transamination, and the rest could 
undergo the degeneration process resulting from the 
instability of PPA. Meanwhile, 24.07  mg/L (0.12  mM) 
IPA was produced at 20 h through TdiD, which was cor-
respondent to only 0.12  mM PPA consumption. There-
fore, a large majority of PPA was transformed into Phe by 
other inherent AATs, such as AspC, TyrB and IlvE [24, 
32] (Fig. 3).
The fermentation results observed during the initial 
20  h indicate that the supply of PPA could efficiently 
enhance IPA production (Fig.  2). However, the growth 
impairment and instability of PPA make it inappropri-
ate to be as an exogenous supplement as is typically 
done with Trp. Furthermore, it is necessary to prevent 
PPA from being utilized by other AATs. Therefore, aug-
mentation of the availability of PPA and blocking the 
Table 1 Strains and plasmids used in this study
Genotype/description Source/references
Strain
 DH5α lacZΔM15 endA1 recA1 relA1 gyrA96 deoR nupG λ− Transgene Bio
 W3110 F− λ− rph-1 INV (rrnD, rrnE) [24]
 WTRCD W3110 with pTRCD This study
 Sun21 W3110 Δ tyrB::FRT, ΔaspC::FRT, tyrA16::Tn10 [24]
 Zhu01 W3110 ΔtyrB, Δ aspC, ΔtnaA, tyrA16::Tn10 This study
 YL01 Sun21 with pTRCD This study
 YL02 Sun21 with pSUFAQ This study
 YL03 Sun21 with pTRCD and pSUFAQ This study
 YL04 Sun21 with p12D and pSUFAQ This study
 YL05 Sun21 with p14D and pSUFAQ This study
 YL06 Sun21 with p16D and pSUFAQ This study
 YL07 Sun21 with p18D and pSUFAQ This study
 YL08 Sun21 with p20D and pSUFAQ This study
 YL09 Sun21 with pDRD and pSUFAQ This study
 YL10 Sun21 with pMOD and pSUFAQ This study
 YL11 Sun21 with pDMD and pSUFAQ This study
 YL12 Zhu01 with p20D and pSUFAQ This study
 YL13 Sun21 with pTAD and pSUFAQ This study
 YL14 Zhu01 with pTAD and pSUFAQ This study
Plasmid
 pET24b-tdiD NdeI/NotI (tdiD) [5]
 pSUFAQ pSU2718 derivative, aroFfbr, pheAfbr, lacIq [24]
 pBJEI-6409 Codon-optimized genes of MEV pathway, Trc promoter Addgene
 pUC57-D Synthetic tdiDco Sangon
 pUC57-18 Synthetic OXB18 promoter Sangon
 pT7D pET24b-tdiD derivative, T7 promoter, tdiDco This study
 pTRCD pT7D derivative, Trc promoter This study
 p12D pTRCD derivative, OXB12 promoter This study
 p14D pTRCD derivative, OXB14 promoter This study
 p16D pTRCD derivative, OXB16 promoter This study
 p18D pTRCD derivative, OXB18 promoter This study
 p20D pTRCD derivative, OXB20 promoter This study
 pDRD p20D derivative, Rom coding sequence deleted This study
 pMOD p20D derivative, origin mutation-108A(108C) This study
 pDMD pMOD derivative, Rom coding sequence deleted This study
 pTAD p20D derivative, tnaA expression cassette This study
 pKD13 bla FRT-kan -FRT [25]
 pKD46 bla αβ exo (red recombinase), temperature conditional replicon [25]
 pCP20 bla cat, temperature sensitive replicon, temperature inducible FLP recombinase [25]
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Fig. 3 Metabolic engineering for IPA biosynthesis in E. coli. Genes of the catalytic enzyme are stated in the boxes. Boxes with solid lines represent 
E. coli inherent genes, boxes with dashed lines represent knockout genes, and boxes with bold lines represent heterogeneous genes expressed in 
plasmids. ANTA anthranilate, CHA chorismate, E4P erythrose-4-phosphate, DAHP 3-deoxy-d-arabino-heptulosonate-7-phosphate, HPP 4-hydroxy-
phenylpyruvate, IPA indole pyruvic acid, L-Phe l-phenylalanine, L-Trp l-tryptophan, L-Tyr l-tyrosine, PEP phosphoenolpyruvate, PPA phenylpyruvate. 
Enzymes coded by genes: aroF, DAHP synthase; aroG, DAHP synthase; aroH, DAHP synthase; aroFfbr, DAHP synthase with feedback inhibition 
resistance; aspC, aspartate aminotransferase; ilvE, branched chain amino acid aminotransferase; pheA, chorismate mutase/prephenate dehydratase; 
pheAfbr, chorismate mutase/prephenate dehydratase with feedback inhibition resistance; tdiD, l-tryptophan:phenylpyruvate aminotransferase; trpE, 
anthranilate synthase; tyrB, aromatic amino acid aminotransferase; tyrA, chorismate mutase/prephenate dehydrogenase
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PPA-consumption branch pathways should be the next 
steps.
Increased PPA pool for IPA production
The PPA formation pathway is part of the shikimate path-
way for aromatic amino acid synthesis in E. coli (Fig. 3). 
Eliminating the branch pathways and side reactions were 
the first considerations for improving the supply of PPA. 
Chorismate (CHA) is the common intermediate of Phe, 
tyrosine (Tyr), and Trp biosynthesis. The Tyr pathway 
can be disrupted via deletion of tyrA. However, the Trp 
pathway is retained in this case since Trp is also a sub-
strate for IPA biosynthesis. In addition, AspC, TyrB, 
and IlvE (branched chain amino acid aminotransferase), 
which are responsible for the conversion of PPA into Phe, 
should be inactivated. According to a previous study [32], 
double deletion of aspC and tyrB can effectively improve 
PPA concentration and enhance the downstream product 
production. Furthermore, knockout of ilvE was shown 
to reduce Phe production, but had little effect on PPA 
or the downstream product, and resulted in a multi-
auxotrophic strain. Therefore, the tyrA, tyrB, and aspC 
mutants [24] were used for IPA biosynthesis in this study 
to limit carbon flux diversion away from the hetero-
gonous pathway (Fig. 3).
The tyrA, tyrB and aspC triple deletion strain Sun21 
[24] generally loses IPA-producing capacity (Fig. 4b). This 
result confirms that TyrB and AspC are the major AATs 
a b
c d
Fig. 4 Culture profiles of W3110, Sun21, YL01, YL02, and YL03 strains. a Growth curve; b IPA production; c Phe concentration; d IPA specific produc-
tion. IPA specific production here refers to the best IPA production obtained during cultivation, except for 0 h, divided by the biomass at the same 
time point. The time-points for IPA specific production of the various strains were dissimilar: W3110 was 25 h, YL01 was 30 h, and Sun21, YL02, and 
YL03 were 50 h
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responsible for basal IPA production. Then, pTRCD was 
introduced into the mutant strain, named YL01. Both 
the Sun21 and YL01 strains exhibited growth inhibition, 
resulting in 88.26 and 84.78% max cell density relative to 
the W3110 strain, respectively (Fig. 4a). This diminished 
cell growth can be attributed to the three inactivated 
genes. Unlike the WTRCD strain in which TdiD along 
with the native AATs work together for IPA synthesis, 
TdiD serves as the only enzyme for IPA production in 
YL01. As shown in Fig.  4b, the W3110 strain accumu-
lated higher IPA production in the first 25  h, while the 
YL01 strain surpassed it in the subsequent 30–45  h of 
fermentation time. By 30 h, the YL01 strain accumulated 
36.72 ± 0 mg/L (18.86 ± 0.32 mg/g DCW) IPA through 
the transaminase activity of TdiD, which was 88.40% IPA 
production and 96.18% IPA specific production relative 
to that of the W3110 strain at 25 h. Therefore, the recon-
stitution of tdiDco in the mutant strain Sun21 largely 
regained Trp transamination ability and restored the 
basal IPA levels of the wild-type strain. The producing 
capacity exhibited by the YL01 strain confirms the prom-
ising role of TdiD in IPA biosynthesis.
In order to elevate the carbon flux in the PPA syn-
thetic pathway and thus effectively enhance the supply of 
precursor, overexpression of the feedback resistance of 
DAHP (3-deoxy-d-arabino-heptulosonate-7-phosphate) 
synthase (aroFfbr) and chorismate mutase/prephenate 
dehydratase (pheAfbr) are common strategies [24, 33]. 
The strains harboring the aroFfbr and pheAfbr expression 
plasmid pSUFAQ [24] in Sun21 and YL01 were YL02 
and YL03, respectively (Table 1). As illustrated in Fig. 4c, 
large amounts of Phe were accumulated in the YL02 and 
YL03 strains, indicating that the carbon flux had been 
redirected to the Phe pathway. Since PPA is a transient 
metabolite and can be rapidly converted into Phe by TdiD 
and the residual IlvE, the quantity of Phe indicated the 
existence of a sufficient PPA pool. However, the YL02 and 
YL03 strains showed significant growth delay. This nega-
tive impact might be caused by the carbon flux decrease 
in the TCA cycle [34]. In spite of this, the maximum cell 
density attained by YL02 and YL03 were similar to that of 
W3110. YL02 produced negligible levels of IPA as Sun21 
since the deficiency of AATs almost abolished IPA forma-
tion in both strains (Fig. 4b). With the reinforcement of 
linear flux from glucose to PPA, YL03 had the highest IPA 
production. The max IPA level was 158.85 ± 5.36 mg/L at 
50  h, which is approximately 3.82-fold higher than that 
of the wild-type W3110. Moreover, YL03 had a max IPA 
specific production of 67.27  ±  2.11  mg/g DCW, cor-
responding to a 3.43-fold improvement compared to 
W3110 (Fig.  4d). As shown in Fig.  4b, the IPA produc-
tion of YL03 increased continually and reached plateaus 
after 45  h. Compared to the IPA production profile of 
YL01 strain (parent strain of YL03, without pSUFAQ), 
this demonstrated that slowly reduced IPA concentra-
tion in YL01 after 30 h was due to the inadequate of PPA, 
not the consumption of IPA and the repressed enzyme 
expression as in W3110.
In previous reports, engineered PPA synthetic path-
ways have been expanded to obtain a lot of valuable 
products [24, 32, 33, 35]. In this study, the PPA path-
way was engineered for enhanced IPA biosynthesis. The 
stimulation of IPA production accompanied by a certain 
amount of Phe production renders the IPA producing 
strain a multi-use platform in the future.
Optimization of tdiDco expression levels
As the IPA production shown above, pTRCD in YL01 can 
only compensate for the loss of the two major multispe-
cific native AATs for IPA formation. This suggests that 
the expression of tdiDco could be a potentially regulatory 
element in IPA biosynthesis.
For fine-tuning gene expression, a constitutive sys-
tem is better than an inducible conditional system [36]. 
Constitutive expression of tdiDco can isolate the exter-
nal effect and sustain amino transfer function through-
out cultivation. A series of constitutive promoters with a 
wide range of strength are likely involved in the regula-
tion. The RecA promoter is a native E. coli promoter with 
strong intensity that is repressed by LexA under normal 
conditions [37, 38]. By abolishing the LexA binding site 
and mutagenesis, Oxford Genetics Ltd. (UK) constructed 
a series of constitutive promoters based on RecA. Among 
them, OXB20 is the most efficient promoter and OXBP1 
is the weakest promoter. With increasing strength, 
OXB12, OXB14, OXB16, OXB18, and OXB20 cover a 
wide range of weak, moderate, and powerful promoters. 
These five constitutive promoters were applied to the 
tdiDco fine tune expression strategy.
Another considerable factor accounting for the modu-
lation of plasmid gene expression is the copy number. 
The absence of ROM coding region leads to a 2- to 3-fold 
increase in plasmid copy number. In addition, a mutation 
108A (108C) in the pBR322 origin could contribute to a 
6- to 8-fold increase in copy number [39, 40]. Based on 
the previous study [40], conducting rom deletion, site-
directed mutagenesis, and the combination of the two 
methods resulted in three high-copy-number vectors 
pDRD, pMOD, and pDMD (Tables 1, 2).
Accordingly, eight plasmids were constructed. p12D, 
p14D, p16D, p18D, and p20D each contained five dif-
ferent constitutive promoters (Table  1). pDRD, pMOD, 
and pDMD had the same OXB20 promoter, but differed 
in plasmid copy number (Tables  1, 2). Theoretically, 
these eight plasmids represent the varying tdiDco expres-
sion levels. These plasmids were co-transformed into 
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Sun21 with pSUFAQ to create the YL04–YL11 strains. 
To explore the effect of different levels of tdiDco expres-
sion on growth, the biomass of these producing strains in 
the final stage of fermentation were examined (Fig.  5a). 
Compared to YL03, the YL04–YL09 strains harboring 
p12D–p20D and pDRD, respectively (Tables  1, 2) had 
no apparent influence on growth and a slight increase in 
final biomass was observed. In contrast, YL10 showed 
minor growth inhibition and YL11 suffered severe 
growth delay; the final dry cell weight of YL11 was only 
about 50% of the other strains. This growth impairment 
might result from the metabolic burden imposed by the 
excessively high copy number.
For the YL04–YL08 strains, the increase in IPA pro-
duction generally correlated with the improvement of 
promoter strength except for YL06 and YL07 (Fig.  5a). 
Remarkably, YL06-YL08 exhibited elevated IPA lev-
els compared to YL03. The production of IPA in YL06 
reached 181.54  ±  11.67  mg/L and YL07 reached 
167.1 ±  4.08  mg/L, which increased 1.14 and 1.05 fold, 
respectively compared to YL03 (Fig. 5a). Moreover, YL08 
showed the best IPA production performance with IPA 
levels of 236.42 ± 17.66 mg/L, a nearly 1.5-fold enhance-
ment compared to YL03. In addition, the ascensive ten-
dency was maintained throughout cultivation (Fig.  5b). 
Constitutive expression strategies have been widely 
applied in metabolic engineering to improve the accu-
mulation of target products [41, 42], and in some cases 
stronger constitutive promoter could bring a better pro-
duction [43]. These results, together with the previous 
reports, demonstrate that the constitutive expression 
and gradual increase of promoter strength promote the 
production. In contrast, the strains with a high-copy-
number plasmid did not produce similar beneficial 
effects. IPA production in YL09 did not significantly 
improve. Moreover, subsequent enhancement of plasmid 
copy number was adverse to IPA accumulation. YL10 
and YL11 exhibited sharply reduced IPA levels when a 
maximum concentration of 28.33  ±  6.32  mg/L (YL10) 
and 22.42 ±  7.27  mg/L (YL11) was obtained. This dra-
matic decreased IPA production was even lower than 
that in the wild-type W3110: only 62.23 and 49.25% of 
Table 2 The strains used in fine-tuning tdiDco expression
a Copy number of pTRCD with the pBR322 origin and rom was identified as 1, p12D, p14D, p16D, p18D, p20D have the same copy number as pTRCD
b pDRD, pMOD, and pDMD in YL09, YL10, and YL11, respectively had increased copy numbers
Strain tdiDco expression plasmid Promoter of tdiDco Relative copy number of tdiDco expression plasmid
W3110 – –
YL03 pTRCD Trc 1a
YL04 p12D OXB12 1a
YL05 p14D OXB14 1a
YL06 p16D OXB16 1a
YL07 p18D OXB18 1a
YL08 p20D OXB20 1a
YL09 pDRD OXB20 2–3 [40]b
YL10 pMOD OXB20 6–8 [40]b
YL11 pDMD OXB20 Approximately 16–24 [40]b
a
b
Fig. 5 a IPA production, IPA specific production and the final 
biomass of W3110 and YL03–YL11 strains. b IPA production and Phe 
concentration of YL03, YL08, YL10, and YL11 strains during cultivation
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that in W3110, respectively. Compared to pTRCD in 
YL01, which was capable of regaining a similar produc-
tion profile to that of W3110, pMOD and pDMD in YL10 
and YL11, respectively, demonstrated diminished TdiD 
value. These results are consistent with a previous study 
[44] showing that the performance of enzyme encoded 
in plasmid did not improve as the plasmid copy num-
ber increased. Furthermore, the extremely high plasmid 
copy number resulted in loss of enzyme activity [33]. In 
addition, in YL10 and YL11, the substantial reduction of 
IPA production was accompanied by a decrease in Phe 
concentration (Fig.  5b). A possible explanation for this 
may be the increased expression of tdiDco induced high 
metabolic stress in E. coli and disturbed the expression 
of pSUFAQ. Despite the same low IPA levels, the mecha-
nism for considerably reduced IPA production in YL04 
was essentially different from that in YL10 and YL11. 
The insufficient tdiDco expression due to the weak pro-
moter strength of OXB12 was responsible for the loss of 
IPA production in YL04. The above findings demonstrate 
that a modest increase in tdiDco expression benefited IPA 
biosynthesis.
Until now, few researches have focused on the direct 
production of IPA. In a previous report, 200 mg IPA was 
obtained from 500 mg Trp through immobilized enzymes 
in a continuous flow reactor [45]. And another research 
achieved preeminent IPA production through a novel 
oxidase when supplied with an enormous amount of Trp, 
but extra catalase was still necessary for reaching the 
highest production [17]. At the shake flask fermentation 
under the condition of 2 g/L Trp, YL08 enabled an effec-
tively enhanced IPA production (236.42 ±  17.66  mg/L), 
and the IPA specific production was 95.69 ±  4.91 mg/g 
DCW, representing a 5.19- and 4.88-fold increase over 
W3110, respectively. However, the max IPA produc-
tion still has not reached a satisfactory level. Based on 
the final IPA and Phe concentrations, even in YL08, only 
25.62% of the PPA pool was employed by TdiD. Despite 
the existence of IlvE as a competitor, the primary reason 
might be the insufficient TdiD catalytic activity. There-
fore, further research should focus on engineering the 
enzymatic activity of TdiD.
tnaA influence on IPA synthesis
Tryptophanase catalyzes the decomposition of Trp into 
indole, ammonium, and pyruvate [46]. Deletion of the 
tnaA gene has been a common strategy for improved Trp 
biosynthesis production in E. coli [47, 48]. The expression 
of tnaA is induced by surplus Trp [49], and is inhibited by 
catabolite repression [50]. However, analysis of IPA bio-
synthesis in E. coli BL21 showed that deletion of tnaA did 
not have a positive effect on IPA production but resulted 
in a 7% reduction (Additional file 1: Figure S1).
To fully explore the potential role of tnaA in IPA pro-
duction, a tnaA knockout strain of Sun21 was con-
structed and named Zhu01. p20D and pSUFAQ were 
simultaneously expressed in Zhu01 to create the YL12 
strain. Furthermore, a complete tnaA expression cassette 
(including Trc promoter and T7 terminator) was inserted 
into p20D, resulting in pTAD. pTAD was co-transformed 
with pSUFAQ in either Sun21 or Zhu01 to generate YL13 
or YL14, respectively. The four strains represent different 
tnaA expression levels (Fig. 7b). IPA production, Trp and 
indole concentration as well as the growth rate of each 
strain were evaluated (Figs.  6, 7). Deletion of tnaA in 
YL12 strain had no significant impact on IPA production, 
and only led to slight decrease of IPA production and 
specific production (91.69 and 96.24% of YL08, respec-
tively) (Fig.  6). On the other hand, the IPA production 
of tnaA overexpression strains (YL13 and YL14) sharply 
declined, which were as low as 32.16 and 31.55% of YL08, 
respectively (Fig. 6). There were no obvious differences in 
Trp concentrations between the four strains throughout 
the cultivation (Fig. 7c). Therefore, the fluctuation in IPA 
production was not due to the Trp availability.
Overexpression of tnaA in YL13 and YL14 strains 
enabled a significant increase in indole production, 
while the deletion of tnaA in YL12 led to the complete 
loss of the indole-producing ability (Fig.  7d). The maxi-
mum indole levels of YL13 and YL14 were both around 
70 mg/L (Fig. 7d). Although up to 357 mg/L indole was 
required for serious inhibition of growth caused by its 
ionophore action [51], a slight growth obstruction could 
still be observed in YL13 and YL14 (Fig. 7a). Despite the 
decomposition of Trp for the certain indole production, 
YL13 and YL14 strains shared similar Trp concentration 
to YL08 strain. Therefore, more carbon flux partitioning 
at the CHA nod of YL13 and YL14 strains might be gov-
erned towards the Trp biosynthesis pathway, such that 
Fig. 6 IPA production and specific production of W3110, YL08, and 
YL12–YL14 strains
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the PPA pool is diminished. The assumption is supported 
by the Phe production in YL13 and YL14 that decreased 
to only 70.78 and 65.17% of YL08 relatively. This could 
explain why YL13 and YL14 both demonstrated reduced 
IPA production. However, the reason for the tenuous 
loss of IPA production as a result of tnaA deletion is still 
unclear. Possible explanations might include the effect on 
TdiD enzyme activity and disturbance of Trp uptake.
IPA production with various concentrations of Trp 
supplement
Even in the best performing strain YL08, certain amount 
of Trp was remained at the end of fermentation (Fig. 7c). 
In order to figure out whether or not there is feedback 
effect of Trp, other than 2 g/L Trp, 0 g/L, 0.5 g/L, 1 g/L 
and 4  g/L Trp were also used to investigate their effect 
on IPA biosynthesis of YL08 strain. The cell growth, IPA 
production and Trp levels of YL08 strain were deter-
mined (Fig.  8). The growth of YL08 in the mediums 
containing various concentrations of Trp were similar 
and better than in the media without Trp supplement 
(Fig.  8a). Without Trp (0  g/L), the IPA production was 
negligible and the IPA production gradually enhanced 
as the exogenous Trp concentration increased (Fig.  8b). 
YL08 strain supplied with 4  g/L Trp has the maximum 
IPA production (318.09 ±  7.56  mg/L), which was 1.34-
fold higher than the IPA production with 2 g/L Trp sup-
plement. Moreover, IPA productivity also elevated as the 
Trp concentration increased. The highest IPA productiv-
ity was obtained with 4 g/L Trp supplement and reached 
6.32  ±  0.36  mg/L/h. Since substrate inhibition usually 
leads to the severely decreased cell mass and product 
ˇˇˉˇ ˇˇˉˉˉˉTnaA expressionin chromosome TnaA overexpressionIn plasmida b
c d
Fig. 7 Culture profiles of W3110, YL08, and YL12–YL14 strains. a Growth curve; b symbols and schematic representation of tnaA expression; c Trp 
concentration; d indole concentration
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formation rate as the substrate concentration increases 
[52, 53], here up to 4  g/L Trp showed no obvious sub-
strate feedback for IPA production.
Provided with 4  g/L Trp, YL08 strain achieved sig-
nificant IPA specific production (137.24  ±  6.37  mg/g 
DCW) (Fig.  8c). However, when the Trp concentration 
increased from 0.5 to 1  g/L, then 2 and 4  g/L, the cor-
responding IPA specific production only had a 1.66-, 
1.57- and 1.46-fold increase respectively (Fig. 8c). As dis-
cussed above, IlvE could be a strong competitor for the 
PPA pool. Thus the limited PPA concentration for IPA 
production might be the main reason for the dispropor-
tionate improvement of IPA specific production as the 
Trp concentration increased. Figure  8d showed the Trp 
concentration profile of the YL08 strain with different 
Trp supplement. From 0 to 40 h, the Trp levels of the cul-
ture decreased slowly, but then started to increase after 
45  h fermentation time. Possible explanation might be 
the endogenous Trp biosynthesis through the shikimate 
pathway.
Consequently, future attempt to increase IPA biosyn-
thesis production should be addressed from improve-
ment of enzyme activity and substrate affinity of TdiD. 
Meanwhile, instead of exogenous supplement, Trp bio-
synthesis from glucose through inherent pathway should 
be performed as well. Strategies [54] for further shiki-
mate pathway engineering could be implemented for 
simultaneous sufficient supply of both Trp and PPA with-
out artificial addition.
Conclusions
In this study, a series of strains for IPA biosynthe-
sis were established. The YL03 strain exhibited a 
158.85  ±  5.36  mg/L IPA production, representing a 
a b
c d
Fig. 8 Culture profiles of YL08 strain supplied with Trp in various concentrations. a Growth curve; b IPA production; c IPA specific production; d Trp 
concentration
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3.82-fold increase over that in the wild-type W3110. 
Furthermore, YL08 showed the best exaltation with IPA 
titers and was capable of producing 236.42 ± 17.66 mg/L 
IPA in flask cultivation. This represents an excellent 
starting point as a new avenue for future IPA biosynthe-
sis via TdiD. Construction of the YL08 strain involved 
engineering the biosynthetic pathway and optimizing 
tdiDco expression levels. Following study aimed at iden-
tifying the role of tnaA in IPA biosynthesis. In addition 
to the consistent unfavorable influence, there was some 
discrepancy between the effects of tnaA deletion and its 
overexpression on IPA production. Finally, the IPA pro-
duction with various concentrations of Trp supplement 
indicated that higher Trp concentration would benefit 
the IPA production. Overall, this study provides detailed 




The strains and plasmids used in this study are listed 
in Table  1. E. coli strain DH5α was purchased from 
Transgene Bio (Transgene Biotechnology Co. Ltd. Bei-
jing, China) for gene cloning. For IPA biosynthesis, E. 
coli strains W3110, mutant Sun21, and plasmid pSU-
FAQ were kindly donated by Professor Sheng Yang (Key 
Laboratory of Synthetic Biology, Institute of Plant Physi-
ology and Ecology, Shanghai Institutes for Biological Sci-
ences, Chinese Academy of Sciences, Shanghai, China). 
Strains were maintained as glycerol stocks at −80  °C. 
The IPA sample was purchased from Sigma. All the 
other chemicals were purchased from Sangon Bio (San-
gon Biotechnology Co. Ltd. Shanghai, China). Restriction 
endonucleases, DNA polymerases, and T4 DNA ligase 
were purchased from Takara Bio (Takara Biotechnology 
Dalian Co. Ltd., China) or Sangon Bio.
Culture media
Lysogeny broth (LB) medium containing 10 g/L tryptone, 
5 g/L yeast extract, and 10 g/L NaCl was used for E. coli 
cultivation. For IPA biosynthesis, E. coli strains were cul-
tured in A medium composed of the following compo-
nents (1 L): 20 g glucose, 2 g (NH4)2SO4, 13.6 g KH2PO4, 
0.2  g MgSO4·7H2O, 7.5  ×  10−3  g CaCl2, 5  ×  10−4  g 
FeSO4·7H2O, 2  g Trp, 0.2  g Tyr, and 3  g aspartic acid. 
The pH was adjusted to 7 by the addition of NaOH. If 
required, antibiotics were added at appropriate concen-
trations: kanamycin 50 g/L, ampicillin 100 g/L, or chlo-
ramphenicol 35 g/L.
Plasmid construction
Gene cloning was conducted according to stand-
ard protocols [55]. Gene splicing and site-directed 
mutagenesis were carried out according to a previously 
published PCR-mediated technique [56]. PCR primers, 
tdiDco and OXB18 promoter were synthesized by Sangon 
Bio. The sequence of tdiDco was deposited in GenBank 
under the accession number KX594383.
All primers used in this study are listed in Additional 
file  1: Table S1. To construct pTRCD, PCR-amplified 
tdiDco from pUC57-D using the primers tdiDco-F/tdiDco-
R was digested with NdeI/NotI and cloned into the NdeI/
NotI site of the tdiD gene removed pET24b-tdiD, result-
ing in pT7D. The tdiDco in pT7D completely replaced 
the tdiD in pET24b-tdiD. Next, the Trc promoter ampli-
fied from pBJEI-6409 with the primers Trc-F-1/Trc-R-1 
was substituted for the T7 promoter at the BglII/NdeI 
site of pT7D to generate pTRCD. The promoter changes 
mentioned below were all performed using the same 
approach through the BglII/NdeI site. The OXB18 pro-
moter was amplified from pUC57-18 using the prim-
ers 18-F/18-R and substituted with the Trc promoter in 
pTRCD to obtain a new plasmid named p18D. OXB12, 
OXB14, OXB16, and OXB20 promoters are mutants of 
OXB18 promoter. To generate the OXB14 promoter, 
two PCR products were amplified from the OXB18 pro-
moter in p18D with the primers 18-F/14-1 and 14-2/18-
R, respectively. Then the two overlapping fragments 
were fused through overlap extension PCR to obtain 
full length OXB14 using the primers 18-F/18-R. The 
OXB14 promoter was subsequently cloned into p18D, 
and replaced the OXB18 promoter to yield p14D. A simi-
lar method was used to construct p20D. Using OXB20 in 
p20D as the template, the promoters OXB12 and OXB16 
were also constructed with different combinations of cor-
responding primers with 18-F/18-R. They were then used 
to obtain plasmids p12D and p16D, respectively. To con-
struct the pDRD plasmid, the linear plasmid backbone 
was amplified from p20D using the primers DR-F/DF-R 
to remove rom and ligated together by the added restric-
tion site SalI. To generate pMOD, the mutational pBR322 
origin was obtained though overlap PCR with primers 
(MO-1 to MO-4) containing the mutation within the ori-
gin region [108A (108C)]. Then, the mutated pBR322 ori-
gin was ligated with the plasmid backbone amplified from 
p20D using primers MO-5/MO-6, by the added restric-
tion site NcoI. Deletion of rom in pMOD was accom-
plished by the same means used for pDRD with the same 
primers DR-F/DR-R to produce pDMD. Construction 
of the tnaA expression cassette consisted of amplifica-
tion of the Trc promoter from pTRCD using the Trc-F-2/
Trc-R-2 primers, amplification of tnaA from W3110 with 
primers tnaA-F/tnaA-R, amplification of the T7 termina-
tor from pTRCD with primers Ter-T7-F/Ter-T7-R, and 
the fusion of the three fragments through overlap exten-
sion PCR. The resulting hybrid sequence amplified from 
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the above three products with primers Trc-F-2/Ter-T7-R, 
which contained the tnaA gene flanked by the Trc pro-
moter and T7 terminator, was incorporated into p20D 
through the single restriction site BglII to generate pTAD.
Construction of tnaA deletion mutant
The deletion of tnaA was achieved using a one-step inac-
tion method [25]. Generally, the PCR fragment used to 
mediate gene replacement for tnaA was amplified from 
pKD13 using the primers p1-tnaA/p4-tnaA and elec-
troporated into the competent Sun21 strain harboring 
pKD46. After confirmation of the replacement by PCR 
with the primers kan-up/kan-down, kanamycin-resist-
ance (KmR) marker was removed by pCP20 to generate 
the finally tnaA deletion strain, Zhu01. Verification of the 
disruption was conducted by PCR with primers up-tnaA/
down-tnaA and DNA sequencing
Shake flask fermentation for IPA biosynthesis in E. coli
Overnight LB medium culture (2 mL) was inoculated in 
250 mL Erlenmeyer flasks containing 50 mL of A medium. 
The cultures were first maintained in a shaker at 37  °C 
and 250  rpm. When the OD600 reached around 0.7–1.0, 
a final concentration of 0.5 mM IPTG was added. For the 
PPA feeding experiment, 1.86 g/L sodium PPA was sup-
plemented at the same time of IPTG. The temperature 
was then reduced to 25  °C for enhanced soluble expres-
sion of proteins. In order to keep the stability of IPA, the 
cultures were kept in dark throughout the growth period. 
Every 5 h, 0.5 mL samples were taken out. A portion of 
the samples were used for cell density tests, and the rest 
were centrifuged at 4 °C and 10,000 rpm for 10 min. The 
supernatants were then stored at −20  °C for subsequent 
IPA and HPLC detection. All the experiments in this 
report were conducted in three independent replicates.
Determination of bacteria biomass
In order to monitor cell growth, the optical density of the 
culture was determined by measuring the absorbance 
at OD600 using an UV2300 UV–Vis (ultraviolet–visible) 
spectrophotometer (Techcomp, Shanghai, China) after 
an appropriate dilution. For the dry cell weight (DCW) 
measurement, 10  mL of culture broth was collected by 
centrifugation at 10,000×g for 10  min in a pre-weighed 
tube. Harvested cell was washed twice with deionized 
water, and then dried at 90 °C to a constant weight. Dry 
cell weight was calculated using the formula obtained in 
this work: DCW (g/L) = 0.28 × OD600.
IPA measurement
Salkowski reagent has been widely used to estimate IAA 
production through a colorimetric method [57–59]. 
The measurement results obtained with the Salkowski 
reagent share a similar dynamic tendency to HPLC 
results [60]. However, an accurate analysis [61] reveals 
that, besides IAA, Salkowski reagent can also react with 
IPA, and indole acetamide (IAM). When used in a reac-
tion with IPA, the Salkowski reagent can provide precise 
measurements of AAT activity, and the accuracy of the 
method has been demonstrated [62]. In this study, with-
out IAA and IAM in E. coli, the Salkowski reagent can be 
a suitable way for IPA quantification.
Among the three formulations of the Salkowski rea-
gent, the PC technique is the most sensitive and spe-
cific [61]. Trp barely responds to the PC reagent, but its 
appearance improves the sensitivity towards IPA. When 
tested, the concentration of Trp in all samples and the 
standard were adjusted to 1  g/L. The supernatant was 
diluted 20 or 40 times with culture medium and water, 
then 0.5 mL of the sample was mixed with 0.5 mL of the 
PC reagent, which consists of 12  g/L FeCl3 and 7.9  M 
H2SO4. After 30  min incubation in the dark at room 
temperature, absorbance was read at 530  nm using the 
UV2300 UV–Vis spectrophotometer. IPA production was 
calculated from the standard calibration curve.
HPLC quantification
The concentrations of Trp, PPA, Phe, and indole were 
determined using an Agilent 1260 series HPLC (Agi-
lent Technologies, USA) equipped with a UV–Vis 
diode array detector. A ZORBAX SB-18 column (5  μm, 
4.6 × 150 mm) maintained at 35 °C was used for sample 
separation. The mobile phase consisted of 0.03% KH2PO4 
water (solvent A) and methanol (solvent B) with a 1 mL/
min flow rate. After injection of 10  μL diluted sample, 
the gradient was proceeded as follows: 20% B (0–2 min), 
60% B (4–8 min), 100% B (14–19 min), and 20% B (20–
25 min). The wavelength used to detect Phe and PPA was 
215 nm, whereas the wavelength used to detect Trp and 
indole was 280 nm.
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